A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study

Gynecologic Oncology

Volumn 121, Issue 1, 2011, Pages 118-121

  Tait, David L ^a   Blessing, John A ^b   Hoffman, James S ^c   Moore, Kathleen N ^d   Spirtos, Nick M ^e   Lachance, Jason A ^f   Rotmensch, Jacob ^g   Miller, David S ^h  

^a CAROLINAS MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NEW BRITAIN GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e Department of Hematology Oncology   (United States)

^f MAINE MEDICAL CENTER   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Endometrial carcinoma; Gemcitabine; Gemzar; Gynecologic Oncology Group

Indexed keywords

CARBOPLATIN; GEMCITABINE; HORMONE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; LYMPHATIC SYSTEM DISEASE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SKIN TOXICITY; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, ENDOMETRIOID; DEOXYCYTIDINE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 79952819390     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.11.027     Document Type: Article

References (26)

1. Horton J, Begg C, Arseneau J, Bruckner H, Creech R, Hahn RG. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 1978;62:159-61. (Pubitemid 8278540)
2. Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. Phase II Trial of Adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1979;63:21-7. (Pubitemid 9152662)
3. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1408-14. (Pubitemid 24206239)
4. Thigpen JT, Blessing J, Lagasse LD, DiSaia PJ, Homesley HD. A phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 1984;3:253-6. (Pubitemid 14112252)
5. Thigpen JT, Blessing J, Homesley H, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1989;33:68-70. (Pubitemid 19106626)
6. Barrett RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II Study of the Gynecologic Oncology Group. Am J Clin Oncol 1993;16:494-6. (Pubitemid 24004100)
7. Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as a second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88:277-81. (Pubitemid 36335809)
8. Thigpen T, Vance R, Balducci L, Blessing J. Chemotherapy inmanagement of advanced or recurrent cervical and endometrial carcinoma. Cancer 1981;48:658-65. (Pubitemid 11058771)
9. Broun GO, Blessing JA, Eddy GL, Adelson MD. A phase II trial of vincristine in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 1993;16:18-21. (Pubitemid 23074774)
10. Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L. Phase II study of Ifosfamide and mesna in refractory adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Cancer 1994;73:1453-5. (Pubitemid 24072552)
11. Dizon DS, Blessing JA, McMeekin DS, Sharma SK, DiSilvestro P, Alvarez RD. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology group trial 129P. J Clin Oncol 2009;27:3104-8.
12. Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, et al. A phase II evaluation of pemetrexed (Alimta, LY31514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2009;115:443-6.
13. Eli Lilly and Company. LY® ; Clinical Investigator's Brochure.
14. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, et al. The management of pancreatic cancer: current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol 2007;18:1-10.
15. Nagel S, Califano R, Thatcher N, Blackhall F. Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. Expert Opin Pharmacother 2007;8:3265-75.
16. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
17. Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010 epub ahead of print.
18. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811-8. (Pubitemid 47123191)
19. Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, et al. Phase I/ II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol 2006 Fletcher Allen Health Care:160-4. (Pubitemid 44374687)
20. Hensley ML, Blessing J, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma. Gynecol Oncol 2008;109:329-34. (Pubitemid 351754961)
21. Therasse P, Arbuck SG, Eisenhauser EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
22. Chen TT, Ng T. Optimal flexible designs in phase II clinical trials. Stat Med 1998;17:2301-12. (Pubitemid 28482675)
23. Smith JA, Brown J, Martin MC, Ramondetta LM, Wolf JK. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 2004;92:314-9. (Pubitemid 38147408)
24. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Oncology Intergroup. J Clin Oncol 2009;27:1419-25.
25. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
26. Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, et al. Adjuvant Gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine Leiomyosarcoma: results of a prospective trial. Gynecol Oncol 2009;112:563-7.